E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the pharmacodynamics (PD) effect of AZD5718 by assessment of urine-leukotriene E4 (u-LTE4) in CAD patients. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of AZD5718 on change from baseline in Coronary Flow Velocity Reserve (CFVR) in CAD patients.
To assess the pharmacokinetics (PK) of AZD5718 after repeated oral dosing in CAD patients
To assess the effect of AZD5718 on coronary flow parameters
To assess the effect of AZD5718 on change in echocardiographic parameters in CAD patients. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
For inclusion in the study patients should fulfil the following criteria:
1. Males and females:
a. Males must be surgically sterile or using an acceptable method of contraception
b. Females must be of non-childbearing potential confirmed at screening by fulfilling one of the following criteria a) postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle-stimulating hormone (FSH) levels in the postmenopausal range, b) documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation
2. Age ≥18 to ≤75
3. BMI ≥18 to ≤35 kg/m2
4. CAD patients, here defined as:
a. ACS 7-28 days prior to study randomization (ACS defined as STEMI, non STEMI event documented by ECG, cardiac enzymes [troponin] and angiogram)
b. Possible post procedure LAD stenosis is <50% and TIMI flow is ≥ 2
5. Provision of signed and dated, written informed consent prior to any study specific procedures |
|
E.4 | Principal exclusion criteria |
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
1 Alanine aminotransferase (ALT) >2 x ULN (i.e., above the normal range) at visit 2, cirrhosis, recent hepatitis, or positive screening test for hepatitis B (hepatitis B surface antigen) or hepatitis C
2 Uncontrolled Type 1 or Type 2 diabetes defined as haemoglobin A1c (HbA1c) Diabetes Control and Complications Trial (DCCT)> 9% or International Federation of Clinical Chemistry (IFCC) >74.9 mmol/mol
3 Patients with atrial fibrillation (chronic or current) or history of ventricular tachycardia requiring therapy for termination, or symptomatic sustained ventricular tachycardia or sick sinus syndrome or AV blockage degree 2-3
4 Patients with pacemaker
5 Prior coronary artery by-pass graft (CABG) to LAD
6 Left ventricle ejection fraction < 30%
7 Unacceptable level of angina despite maximal medical therapy or unstable angina at entry Canadian Cardiovascular Society (CCS) ≥ 3 (Visit 1 or Visit 2)
8 Stroke within the previous 6 months from ACS or ongoing treatment with Persantin or Asasantin
9 Planned treatment with zileuton, leukotriene receptor antagonists (e.g. montelukast), coumadin or steroids during trial
10 Planned statin therapy dose regimen changes during trial
11 Chronic use of anticoagulants on therapeutic dose (not including thrombosis prophylaxis) during the study
12 Planned additional cardiac intervention (e.g., PCI, CABG) within next 6 months
13 NYHA class III-IV heart failure at discharge or hospitalization for exacerbation of chronic heart failure within the previous 3 months from ACS
14 Previously known severe renal disease (CKD stage 4 or 5) or previously known creatinine clearance calculated by Cockcroft Gault equation <30 ml/min*m2
15 Aortic or mitral valvular disease or valvular disease classified as severe
16 Known allergy to adenosine
17 Known elevated intracranial pressure
18 Heart rate < 40 bpm
19 Systolic blood pressure < 90 mmHg
20 Asthma or COPD with strong reactive component in judgment of investigator
21 Treatment with dipyridamole, theophyllamine, fluvoxamine, rifampicin, fenytoin or carbamazepine
22 Inability to comply with the study protocol
23 History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity to drugs with a similar chemical structure or class as study drugs
24 Patients unable to give their consent or communicate reliably with the investigator or vulnerable patients e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
25 Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
26 Participation in another clinical study with an investigational product during the last 3 months
27 Previous randomization in the present study
28 Known history or current abuse of drugs or alcohol |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy variable will test the null hypothesis that patients given AZD5718 200mg have less than 80% inhibition of u-LTE4 compared to placebo, versus the alternative hypothesis that patients given AZD5718 200mg have equal or more than 80% inhibition of u-LTE4 compared to placebo (one-sided 97.5% confidence interval). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Percentage change at Visit 4 from baseline (Visit 2) in creatinine-normalised u-LTE4. Summary statistics per time point the variables are measured will also be presented. |
|
E.5.2 | Secondary end point(s) |
The following secondary efficacy variables are all measured as change from baseline:
CFVR
LAD resting mean diastolic flow velocity
LAD hyperaemic flow velocity
Measurements of left ventricular (LV) systolic and diastolic function, more specifically
LV ejection fraction (LVEF) at rest
LV Global Longitudinal Strain (GLS) at rest and at hyperaemia
LV Global Circumferential Strain (GCS) at rest and at hyperaemia
LV longitudinal early diastolic strain rate
Summary statistics per time point the variables are measured will also be presented. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Percentage change at Visit 4 from baseline (Visit 2) in creatinine-normalised u-LTE4. Summary statistics per time point the variables are measured will also be presented. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 11 |